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Aim: Multiple myeloma (MM) is a malignant neoplasm of plasma cells (PC) derived from the bone marrow (BM) origin. The 
present case report was aimed to monitor the efficiency of lenalidomide-based combined therapy (LBCT) induced alterations 
in serum proteins of 42-year-old female MM patient. Besides, in the context of case report we also present an overview of the 
literature describing LBCT. Study design: Serum protein electrophoresis (SPEP) was performed in three visits (V1-V3) to monitor 
the disease status of the patient and her treatment response to LBCT. Level of monoclonal protein (M-protein) was measured 
through cellulose acetate zone electrophoresis and quantified by densitometer in follow-up investigations after therapy intervals. 
Results: A significant reduction of M-protein in γ-globulin region was observed (P < 0.007) after receiving LBCT. However, the 
condition depicted hyper γ-globulinemia. β-globulin (P < 0.002) and α2-globulin (P < 0.047) was suppressed from the initial visit 
and subsequent follow-up also indicated the status of hypoglobulinaemia. Although, serum albumin level was found to be increased 
after therapy (P < 0.016), hypoalbuminaemia was also noticed before and after LBCT. Conclusion: On the basis of this case report 
and pertinent literature, we conclude that LBCT is more efficient in the treatment of MM and has significant role in serum protein 
alterations especially in the reduction of M-protein in the MM patients.
Key Words: disease response monitoring; lenalidomide-based combined therapy; multiple myeloma; three visits follow-up; serum 
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Multiple myeloma �MM� is a malignancy of plasma 
cells �PC� of �one marrow �BM� [�]. MM �egins with 
the elevated num�er of PC secretes whole monoclonal 
immunoglo�ulin’s �Ig� or high level of homogenous 
M-proteins [�]. M-protein secreting PC grows pri-
marily in the BM cavities and proliferates from one 
cavity to another. MM may progress as asymptomatic 
or symptomatic forms and their complications include 
unexplained �one pain� typical elevated serum protein 
or urinary protein� hypercalcemia� renal impairment� 
amyloidosis� immunodeficiency and anemia [�� �].
Hematological� �iochemical� radiological and im-
munological investigations have gained more atten-
tion in esta�lishing the diagnosis and management 
of MM. SPEP is the one considered as a hallmark im-
munological investigation in the diagnosis of MM over 
years. SPEP identifies clinically significant M-protein 
spike or paraprotein. M-protein is a tumor marker for 
monoclonal gammopathies used to monitor the dis-
ease status. Monoclonal gammopathy is defined with 
a homogeneous spike-like peak in a focal region of the 
γ — glo�ulin [5]. Based on the diagnosis including 
SPEP� MM patient must �e su�jected to chemotherapy 
in a plateau state or for one year [�]. Many novel drugs 
like �ortezomi�� thalidomide and lenalidomide has 
made �etter understanding of MM treatment su�stan-
tially over the last decade [�]. 
Lenalidomide� an amino-su�stituted thalidomide 
derivative is the current choice of drug to treat MM� due 
to its high �eneficial �iological and pharmacological 
properties in management of the disease. It is a well-
known oral immunomodulatory drug �IMi�� that 
lacks the toxicological profile of thalidomide includes 
significant peripheral neuropathy� somnolence� and 
constipation [8� 9]. It has a remarka�le in vitro and 
in vivo activity. Lenalidomide directly induces tumor 
cell apoptosis [��]. Lenalidomide has the potential 
to modify ligand induced cellular responses like tumor 
necrosis factor-α �TNF-α� and interleukin-�β �IL-�β�. 
It also stimulates the anti-inflammatory cytokine inter-
leukin-�� �IL-��� [��� ��]. Lenalidomide has a limited 
toxicity in MM and myelodysplastic patients [��].
International uniform response criteria for MM also 
recommended that patients undergoing therapy 
and their measura�le disease must �e tracked and 
assessed with SPEP [��]. Keeping in view of the 
recommendations� the case presented here was 
monitored for the therapeutic alterations induced 
�y lenalidomide-�ased com�ined drugs �LBC�� 
through SPEP. Besides� in the context of case report 
we also present an overview of the literature descri�-
ing similar therapy.
CASE REPORT
A ��-year-old Indian female who initially presented 
with lower �ack ache. She is a known hypertensive with 
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to�acco chewing ha�it. Her past medical history was 
remarka�le with hysterectomy a�out seven years ago. 
She was examined �y primary care physician reported 
pedal oedema and tenderness in lum�ar spine. She was 
sent for MRI lum�osacral spine. MRI report revealed 
generalized osteoporotic changes in spine� indicated 
the possi�ility of multiple focal BM neoplastic lesions. 
Finally� she was su�jected to whole �ody scan with 
Tc-99m revealed multiple �ony metastases. She also 
had complete �lood profile and �iochemistry test done 
and the most nota�le finding showed Total Leucocyte 
Count �TLC� ��.��� with an Hg� of 9.8 g/dL and �lood 
urea �9%. Rest all other investigations were normal. 
Additional studies recommended �y the oncologist 
included SPEP.  
Clinical Sample and SPEP. The study was con-
ducted in accordance to the ethical norms of Insti-
tutional human ethical committee. Peripheral �lood 
sample were collected in no additive anticoagulant-free 
vacutainer tu�es �VAKU-8� HM� Healthcare� UK� from 
the patient through department of patho logy� Jawaha-
rlal Nehru Cancer Hospital & Research Centre� Bhopal. 
Zone electrophoresis was performed immediately 
within two hours after serum separation. Sera were 
electrophoresed on cellulose acetate paper �Sarto-
rius� Germany� Electrophoresis unit �Bangalore Genei� 
Bangalore� at �� V with Tris — Borate — E�TA �pH 8.�� 
�uffer conditions previously descri�ed �y us [�5� ��]. 
The �ands were separated till the dye front reaches 
the end of cellulose acetate paper and then stained 
with Ponceau S stain �S.d fine chemicals� Mum�ai� 
and destained with �% acetic acid for �� min. Serum 
protein �ands for each fraction were quantified for their 
a�solute values in densitometer �Systronics� India�.
Diagnosis and chemotherapy regimen. Initial 
SPEP analysis of the patient on visit � �V�� revealed 
a discrete high intense �and confirmed the presence 
of M-protein or strikingly elevated spike in the γ–
glo�ulin region. Accordingly to the diagnosis� she was 
su�jected to radiotherapy and chemotherapy with the 
com�ined regimen of lenalidomide ��5 mg� once a day 
�O��� �examethasone ��� mg/week� and I�andronic 
acid �Bisphosphonate� �9 mg/week�. Enoxaparin 
��.� ml/O��� Morphine �� mg/O��� and Metoclo-
pramide �5 mg/O�� were administered as supportive 
drugs in the regimen. She completed the first cycle 
LBCT in two weeks. �ue to the complaint of continuous 
vomiting� weakness and pain she was advised to stop 
lenalidomide. After nine days� she started once again 
LBCT as second cycle included anti�iotics Amikacin 
��5� mg/O�� and Nitrofurantoin ���� mg/� days� due 
to �acterial infections. To monitor the disease and its 
response to LBCT in the patient� we collected serum 
samples of visit � �V�� after two weeks of initial therapy 
�at the end of first cycle� and visit � �V�� after two weeks 
completion of the second cycle of lenalidomide. In all 
the visits� SPEP was performed and analyzed as men-
tioned a�ove. 
Statistical analysis. Statistical analysis was done 
using Graph Pad InStat �GPIS� Ver. �.�5. One Sample 
T test were used to analyze the cumulative results in 95% 
confidence interval� at p < �.�5 significance level.
RESULTS
�isease status and response to LBCT was monitored 
through SPEP in a female MM patient. Comparative 
analysis was made among the individual protein frac-
tions �al�umin� α�-glo�ulin� α�-glo�ulin� β-glo�ulin and 
γ-glo�ulin� among initial and follow — up visits �V��V��.
More significantly� a remarka�le reduction of M-pro-
tein spike or sharp intense �and in the γ-glo�ulin 
region was o�served in V� and V� when compared 
to V� �59.85±�.9�� �p < �.����. Although� the level 
of M-protein was declined� percentage of γ-glo�ulin was 
higher and a�ove the normal range even after therapy. 
Since from V��V�� β-glo�ulin ��.9�� ± �.��� �p < �.���� 
and α�-glo�ulin �5.��� ± �.�8� �p < �.����� was markedly 
suppressed and noticed as sharp faint �and conside-
ra�ly declined from the normal range. In all three visits� 
α�-glo�ulin was seen as a faint �and and appeared within 
the reference range �8.��� ± �.��� �p < �.����.
Al�umin appeared as a light diffused �and and 
slightly increased after the therapy of V� and V� as com-
pared to V� ���.�� ± �.�5� �p < �.����. However� the low 
serum al�umin level failed to attain the normal range 
in V� and V� �Ta�le� Figure�.
Table. Serum protein profile of MM patient in three consequent visits 
Serum proteins 
(refe rence range, %) V1 (BT) V2 (AT) V3 (AT) Mean ± SE
One sample 
t-test
Albumin (42–60) 16.33 23.79 25.21 21.77±2.75 t = 7.907
p < 0.015*
α1-globulin (2–11) 3.92 10.91 9.36 8.06±2.12 t= 3.804
p < 0.063
α2-globulin (9–21) 7.79 3.38 5.98 5.72±1.28 t = 4.467
p < 0.047*
β-globulin (4.5–15) 3.16 2.72 2.84 2.91±0.13 t = 22.135
p < 0.002*
γ-globulin (9–25) 68.78 59.17 51.61 59.85±4.97 t = 12.047
p < 0.007*
Notes: BT — before therapy; AT — after therapy; * — significance.
Elevated Decreased
γ-Globulin
β-Globulin
α2-Globulinα1-Globulin
Albumin
γ-Globulin
β-Globulin
α2-Globulin
α1-Globulin
Albumin
γ-Globulin
β-Globulin
α2-Globulin
α1-Globulin
Albumin
V1 V2 V3
Figure. Protein profile in serum of MM patient showing the 
discrete intense �and of “Myeloma Protein” decreased after 
receiving LBCT — Elevated — �ecreased
DISCUSSION
MM is an uncommon cancer occurs approximately 
�����% of all hematological malignancies �HM� 
[��]. Several anticancer chemotherapeutic drugs are 
known to alter the immune cell functions and also 
used as an immunosuppressant [�8]. Lenalidomide 
is an IMi�� frequently used to treat MM� HM and solid 
tumors. Hence� the case presented here was monitored 
for the therapeutic effects of LBC� on serum proteins.
Many studies suggested that the LBCTs are highly 
effective to treat MM. Even though lenalidomide has 
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an antitumor activity� some MM patients do not respond 
to monotherapy [�9]. Lenalidomide monotherapy 
in MM may possi�ly delay in complete remission �CR� 
of the disease and drug must �e administered for a long 
period to achieve sta�le remission. Such long adminis-
tration may cause side effects. A phase II study revealed 
�5% of relapsed or refractory MM patients treated with 
lenalidomide showed a complete and partial response. 
However� these patients failed to respond lenalidomide 
monotherapy� �9% of the patients responded after the 
addition of oral dexamethasone [��]. Another study 
o�served lenalidomide plus dexamethasone com�ined 
therapy as a highly effective regimen to treat refractory 
MM as compared to the old therapy consisting of high-
dose dexamethasone alone [��].
An open-la�el phase II trial� studied �� symptom-
atic MM naive patients received oral lenalidomide 
��5 mg/O�� for �� days� clarithromycin �5�� mg� twice 
daily� and dexamethasone ��� mg� once weekly every 
�8 days. This study significantly o�served a reduction 
of serum M-protein ≥ 5�% and urine M-protein ≥ 9�% 
was noticed in 9�% of patients �n = �5�. Maximum 
complete response rate was �9%� with ��% of patients 
showed a decrease in M-protein levels around 9�% 
[��]. The response rate of other LBC� regimen ��exa-
methasone� �ortezomi� and cyclophosphamide� 
is also more encouraging in the treatment of relapsed 
or refractory MM achieved CR [9].
Our patient has shown a remarka�le response after 
receiving the LBCT demonstrated the sta�le reduction 
of M-protein. Considera�le decrease of M-protein level 
indicated patient’s response to com�ined therapy. How-
ever� hyper γ-glo�ulinemia was retained in the patient 
even after the therapy. Furthermore� the com�ined 
regimen is highly effective than any other monotherapy 
and administered regularly to achieve CR in the patient. 
Regular administration of lenalidomide may have re-
duced side effects in the MM patient [��].
Besides� other glo�ulin proteins �β and α�� persisted 
in a suppressive state indicated the condition of hypo-
glo�ulinaemia �efore and after therapy. Remarka�ly� 
the status of α�-glo�ulin was normal in the patient even 
after receiving two cycles of lenalidomide. Low serum 
al�umin level or hypoal�uminaemia commonly occurs 
in myelo�lastic or lympho�lastic leukemic events [��]. 
In agreement to this hypothesis� hypoal�uminaemia 
was also existed in the patient �efore and after therapy� 
a slight increase in al�umin status indicated the posi-
tive response only after the initial therapy. However� the 
case report presented here illustrated the condition 
of monoclonal gammopathy in all three visits. 
The present case findings are concordance to the 
report of We�er et al. [��] and Niesvizky et al. [��]� 
suggested that CR in MM patients can �e achieved 
on LBCT. However� the present study failed to monitor 
the MM patient till CR� due to her irregular follow-up and 
discharge. But� this three visit follow-up noticed a �etter 
response of the MM patient on LBCT. It is also notewor-
thy to mention that LBCT has a significant role in the 
reduction of M-protein. This reduction may �e due to the 
immunomodulating activity of lenalidomide. On the 
�asis of case report we suggest that LBCT regimen 
is effective against MM and must �e implemented for 
treating other cancers similar to MM. 
Although this follow-up report has few limitations� 
the case reported here exhi�its the advantage and 
efficiency of LBCT� which could �e useful to the la�ora-
tory clinicians and oncologists in treating MM. Effective 
treatment of cancer needs a proper chemotherapeutic 
regimen and monitoring attains CR in the patients. 
Hence� this kind of case report is essential in future 
to reveal the therapeutic effect of drugs in cancer 
treatment.
In summary� this case report highlights the signifi-
cance of monitoring serum protein alterations espe-
cially M-protein through SPEP. We conclude that LBCT 
has a potent role in treating MM. 
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